A Novartis cholesterol drug that cardiologists called a sure thing failed to prevent a single heart attack or stroke in a massive clinical trial — and the years of corporate hype that preceded the bust show how the pharmaceutical pipeline burns through American money on shareholder promises before the science is in.
The drug, pelacarsen, was designed to lower lipoprotein(a), a genetic form of cholesterol that roughly 1 in 5 Americans carry and can't control through diet or exercise. It did that job beautifully — cutting Lp(a) levels by 78% compared to placebo. But according to results presented Saturday at the American Heart Association and published in the New England Journal of Medicine, that huge reduction translated into zero measurable impact on heart attacks, strokes, cardiovascular deaths, or procedures to open blocked arteries.
Dr. Steven Nissen, the Cleveland Clinic cardiologist who led the 8,322-person Horizon trial, told CNN the results weren't even close: "It wasn't a near miss. It just didn't have an effect on outcomes, and I don't think virtually anybody's prepared to hear that."
NBC News framed the outcome as a "massive blow to preventive cardiology." CNN led with the emotional shock to doctors. Neither outlet pressed on the structural question: how does a drug get this far — with tens of millions already sunk, per CNN — on uniform expectations rather than evidence?
"I really thought that this was going to be a slam dunk," said Dr. Amanda Doran of Vanderbilt University Medical Center, one of nearly 800 trial sites. Dr. Karol Watson, a UCLA preventive cardiologist not involved in the research, told NBC News: "I have not seen a more shockingly neutral trial in a while."
One theory for the failure: the intervention came too late. The average participant was 60, and Lp(a) is elevated from conception. "If we just swooped in in the last five years, maybe that's too late," Watson said. Participants were also aggressively treated for other risk factors — LDL cholesterol, blood pressure — which may have left little room for pelacarsen to show a benefit.
Novartis is now abandoning the drug entirely.
The broader pattern is what matters for ordinary Americans. The FDA's revolving door with the pharmaceutical industry — where regulators and drug executives cycle through the same positions — creates a system where corporate projections and biomarker reductions are treated as proxies for patient outcomes. Drugs get fast-tracked, investment piles up, and the bill eventually lands on American families at the pharmacy counter. When the science finally arrives, as it did Saturday, the companies walk away. The patients who needed a real breakthrough don't get one.
Pelacarsen reduced a number on a lab report. It didn't save a single life. The question neither outlet asked: how many more "slam dunks" are sitting in the pipeline, backed by the same institutional confidence, waiting to miss?
